<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689520</url>
  </required_header>
  <id_info>
    <org_study_id>CV1/01</org_study_id>
    <secondary_id>CV1/01</secondary_id>
    <nct_id>NCT00689520</nct_id>
  </id_info>
  <brief_title>Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis</brief_title>
  <official_title>Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether low-molecular-weight heparin could be
      equally or more effective than oral anticoagulation in the long-term treatment of deep venous
      thrombosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The open-label prospective randomized clinical trial compares subcutaneous LMWH
      (tinzaparin)administered for 6 months versus initial treatment using subcutaneous LMWH
      followed by oral anticoagulants given for a similar period of time in patients with proximal
      venous thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of symptomatic recurrent venous thromboembolism</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major bleeding</measure>
    <time_frame>6 month treatment interval</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>tinzaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acenocoumarol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tinzaparin for 1 weeks followed by acenocoumarol for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinzaparin</intervention_name>
    <description>tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months</description>
    <arm_group_label>tinzaparin</arm_group_label>
    <other_name>innohep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acenocoumarol</intervention_name>
    <description>tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months</description>
    <arm_group_label>acenocoumarol</arm_group_label>
    <other_name>Vitamin K antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive, symptomatic patients with a first or recurrent episode of acute
             proximal-vein thrombosis of the lower limbs.

          -  either sex and over 18 years of age

          -  referred to the Vascular Surgery Department of the hospital

          -  onset of symptoms less than 2 weeks

          -  documented by compression ultrasonography,

        Exclusion Criteria:

          -  received heparin, low-molecular-weight heparin or oral anticoagulant therapy for more
             than 2 days for the present disease

          -  pulmonary embolism requiring thrombolytic therapy

          -  Need of surgical thrombectomy or vena cava interruption

          -  receiving oral anticoagulant treatment or antiplatelet agents for other conditions

          -  contraindication to anticoagulant treatment (active bleeding, severe blood pressure or
             allergy to the study drugs)

          -  platelet count lower than 100x103 /μl or hemoglobin concentration lower than 7 g/dl or
             history of heparin-associated thrombocytopenia

          -  severe renal failure necessitating dialysis

          -  pregnancy

          -  lumbar puncture within the previous 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Romera, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoni Romera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oriol Lapiedra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Creu Roja de l'Hospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vascular surgery service. Hospital Creu Roja de l'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08906</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery. Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>June 2, 2008</last_update_submitted>
  <last_update_submitted_qc>June 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Romera, Antonio MD</name_title>
    <organization>Department of Vascular Surgery. Hospital Universitari de Bellvitge</organization>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>Vitamin K antagonist</keyword>
  <keyword>Longterm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

